Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Nls Pharmaceutics Ltd WT
(NQ:
NLSPW
)
0.0090
UNCHANGED
Streaming Delayed Price
Updated: 3:14 PM EDT, Oct 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Nls Pharmaceutics Ltd WT
< Previous
1
2
3
4
Next >
NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
June 15, 2023
Via
ACCESSWIRE
NLS Pharmaceutics Announces Positive Safety Data From In Vitro CYP450 and Transporter Mediated Drug-Drug Interaction Studies of Mazindol
June 14, 2023
Via
ACCESSWIRE
NLS Pharmaceutics Appoints Keith Harrison Dewedoff as Interim Chief Financial Officer
May 08, 2023
Via
ACCESSWIRE
NLS Pharmaceutics Announces Purchase Agreement with BVF Partners L.P. to Raise Aggregate Gross Proceeds of up to $30 Million
December 07, 2022
Via
ACCESSWIRE
NLS Pharmaceutics Appoints Dr. George Apostol as Chief Medical Officer and Global Head of Research & Development
September 08, 2022
Via
ACCESSWIRE
NLS Pharmaceutics Presents Latest Clinical and Preclinical Data at SLEEP 2023
May 04, 2023
Via
ACCESSWIRE
NLS Pharmaceutics Receives Green Light from the U.S. FDA to Proceed with Phase 3 Clinical Program (AMAZE) for Quilience(R) (Mazindol ER) for the Treatment of Narcolepsy
May 02, 2023
Via
ACCESSWIRE
NLS Pharmaceutics Presents Latest Preclinical Pipeline Data at American Society of Clinical Psychopharmacology
April 25, 2023
Via
ACCESSWIRE
NLS Pharmaceutics Announces Open Label Extension Study Six-Month Data for Quilience(R) (Mazindol ER) in the Treatment of Narcolepsy Type 1 and Type 2
March 27, 2023
Via
ACCESSWIRE
NLS Pharmaceutics to Present at the 35th Annual Roth Conference
March 01, 2023
Via
ACCESSWIRE
NLS Pharmaceutics Announces Completion of Open Label Extension Study with Quilience(R) (Mazindol ER) for the Treatment of Narcolepsy
January 30, 2023
Via
ACCESSWIRE
NLS Pharmaceutics Regains Compliance with Nasdaq Stockholders' Equity Requirement
January 25, 2023
Via
ACCESSWIRE
NLS Pharmaceutics Announces New In-Vitro Data Reconfirming Quilience's(R) (Mazindol ER) Unique Dual Mechanism of Action Involving Significant Orexin-2 Receptor Activity
January 23, 2023
Via
ACCESSWIRE
NLS Pharmaceutics Announces an R&D Update Webcast to Review the Company's Growing Portfolio of Pre-Clinical Compounds
January 12, 2023
Via
ACCESSWIRE
NLS Pharmaceutics Announces Compliance with Nasdaq Bid Price Requirement
January 12, 2023
Via
ACCESSWIRE
NLS Pharmaceutics to Participate in Upcoming Investor Conferences
January 11, 2023
Via
ACCESSWIRE
NLS Pharmaceutics CEO Issues Letter to Shareholders
December 22, 2022
Via
ACCESSWIRE
NLS Pharmaceutics Announces Closing of Initial Tranche of US$10.0 Million Purchase Agreement with BVF Partners L.P.
December 14, 2022
Via
ACCESSWIRE
NLS Pharmaceutics Announces Receipt of Nasdaq Minimum Bid Price Notification
December 07, 2022
Via
ACCESSWIRE
NLS Pharmaceutics Announces Notice of Allowance for U.S. Patent Covering Mazindol for Opioid Dependence and Substance Use Disorder
December 01, 2022
Via
ACCESSWIRE
NLS Pharmaceutics Announces Launch of Paid for Named Patient Program with Mazindol ER for Idiopathic Hypersomnia, a Serious Sleep Disorder with No Approved Treatment Options in Europe
November 23, 2022
Via
ACCESSWIRE
NLS Pharmaceutics Successfully Appeals Nasdaq Delisting Notice
November 14, 2022
Via
ACCESSWIRE
NLS Pharmaceutics Provides Open Label Extension Study Update for Quilience(R) (Mazindol ER) in the Treatment of Narcolepsy
November 07, 2022
Via
ACCESSWIRE
U.S. FDA Grants Orphan Drug Designation (ODD) for Quilience(R) (Mazindol ER) for the Treatment of Idiopathic Hypersomnia (IH)
November 02, 2022
Via
ACCESSWIRE
NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing
October 05, 2022
Via
ACCESSWIRE
NLS Pharmaceutics Announces $4 Million Private Placement and Conversion of Existing Short-Term Notes
October 03, 2022
Via
ACCESSWIRE
NLS Pharmaceutics Announces Positive Top-Line Results from its Phase 2a Clinical Trial of Once-Daily Quilience(R) (Mazindol ER) for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy
September 27, 2022
Via
ACCESSWIRE
NLS Pharmaceutics To Host Virtual Key Opinion Leader Event on September 30, 2022 After Release of Quilience(R) Top-Line Phase 2a Narcolepsy Results
September 19, 2022
Via
ACCESSWIRE
NLS Pharmaceutics Announces Decision by Japanese Patent Office to Grant Patent in Japan for Mazindol Extended-Release
July 28, 2022
ZURICH, SWITZERLAND / ACCESSWIRE / July 28, 2022 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP), (Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the...
From
NLS Pharmaceutics AG
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
NLS Pharmaceutics Announces Decision by Japanese Patent Office to Grant Patent in Japan for Mazindol Extended-Release
July 28, 2022
Via
ACCESSWIRE
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.